Post Profile






Reporting of adverse events in targeted therapy and immunotherapy trials is 'suboptimal'

(European Society for Medical Oncology) A significant number of trials of targeted therapies and immunotherapies in recent years show suboptimal reporting of adverse events, particularly the reporting of recurrent or late toxicities and the duration of the adverse events.
read more

share

Related Posts


Vaccine Targets Malignant Brain Cancer Antigens, Significantly Lengthens Survival

Health : Newswise Medical News

An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy.

Immunotherapy Authority Joins Rush Cancer Leadership

Health : Newswise Medical News

A leading authority on developing innovative immunotherapy treatments is Rush' new division chief of the Hematology, Oncology and Cell Therapy. Dr. Dr. Timothy Kuzel, a leading expert on cancer immunotherapies, will focus on continu...

Innovative Targeted Payload Therapy Demonstrated Extension of Overall Survival to 9.1 Months in Elderly Patients with Secondary Acute Myeloid Leukemia

Health : Newswise Medical News

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow ...

Clinical Trial Analysis Suggests Drug Combination May Be Highly Effective in Recurrent Ovarian Cancer

Health : Newswise Medical News

Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Pazopanib Shows Promise In Phase II Trial For Relapsed/Refractory Urothelial Cancer

Health : Medical News Today

An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (...

Comments


Copyright © 2016 Regator, LLC